Qiagen (QGEN) announced the launch of QIAstat-Dx Rise – a version of the QIAstat-Dx automated syndromic testing system that offers throughput. The new system, which received clearance from the FDA, is designed to meet the needs of hospitals and reference laboratories seeking highly automated syndromic testing with automated loading and unloading of cartridges, access to priority handling of samples and only a minimum of hands-on time.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QGEN:
- Qiagen’s Voting Rights Announcement Involves BlackRock’s Significant Holdings
- Qiagen Announces Voting Rights Notification by BlackRock
- Qiagen Announces Major BlackRock Shareholding
- Qiagen Receives Notification of BlackRock’s Significant Stake
- Qiagen Releases Q2 2025 Financial Report Highlighting Asset Growth